Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2013
March 2013, Vol 4, No 3
March 2013, Vol 4, No 3
Perspectives of Quality Care in Cancer Treatment: A Review of the Literature
By
Lisa M. Hess, PhD
;
Gerhardt Pohl, PhD
March 2013, Vol 4, No 3
Background:
Although information about quality care is increasingly available, there remains a gap in knowledge regarding stakeholders’ perceptions of quality cancer care. It is important to maintain high quality of patient care, but perspectives of quality may differ by stakeholder.
Read Article
Is Oral Electrolyte Replacement More Effective than IV Replacement in the Oncology Population?
By
Joanne Growney, RN, MA, ANP-BC
;
Rebecca Martin, BSN, RN, OCN
March 2013, Vol 4, No 3
Background:
Electrolyte abnormalities are the most common laboratory findings in patients with malignancies. Clinical manifestations of several electrolyte deficiencies occur with frequency in malignancy (Hawthorne JL, Schneider SM, Workman ML). Patients who are admitted for chemotherapy regimens as well as for complications post chemo receive electrolyte replacements on a daily basis. Experience has shown consistent patient and staff nurse dissatisfaction with the current replacement protocol.
Read Article
Cost Considerations for New Oral Therapies for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously
By
Zoe Clancy
;
Lorie A. Ellis
;
R. Scott McKenzie
;
Mekré Senbetta
March 2013, Vol 4, No 3
Background:
Two oral agents for mCRPC patients who previously received docetaxel were recently approved by the US Food and Drug Administration—abiraterone acetate plus prednisone (AA+p) and enzulatamide (EN). Phase 3 studies in this population showed median treatment duration of 8 months for AA+p1 and 8.3 months for EN,2 while median survival was 15.81 months and 18.42 months, respectively. The budgetary impact of these products to payers depends, in part, upon real world treatment duration and the proportion of mCRPC patients utilizing each product.
Read Article
Cost Analysis of Bortezomib Retreatment Compared with Switching to Carfilzomib in Patients with Relapsed Multiple Myeloma Previously Treated with Bortezomib
By
Abbie Ba-Mancini, MBA
;
Mei Sheng Duh, MPH, ScD
;
Jonathan Gravel, MS
;
Kevin B. Knopf, MD, MPH
;
Marie-Hélène Lafeuille, MA
;
Patrick Lefebvre, MA
;
Esprit Ma, MPH
;
Liviu Niculescu, MD
March 2013, Vol 4, No 3
Background:
In an era of multiple effective treatment options for relapsed/refractory multiple myeloma (MM), a recent meta-analysis has shown that retreatment with bortezomib continues to be an effective option in previously treated patients who relapsed.
Read Article
Imatinib Can Still Be Used as 1st-Line for Treating Chronic Myelogenous Leukemia
By
Wesley Wong, PhD
March 2013, Vol 4, No 3
Background:
The introduction of tyrosine kinase inhibitors (TKIs) into clinical practice resulted in a very dramatic prolongation of survival for most, but not all patients with chronic myeloid leukemia (CML) in chronic phase. If properly managed, and if adherence is greater than 80%, the 10-year survival rate reaches 85% for patients treated with the 1st-generation (Gen) TKI, imatinib (Gleevec).
Read Article
Wait Time and Patient Satisfaction—Improving Outcomes Can Be as Easy as Child’s Play
By
Ann Bredensteiner
;
Julia Whiteker
March 2013, Vol 4, No 3
Background:
Breast Care at IU Health North Hospital is a multidisciplinary clinic comprised of breast surgeons, medical and radiation oncologists, plastic surgeons and geneticists. It has consistently achieved excellent patient satisfaction scores; however, one area needing improvement was in office wait time.
Read Article
Say Ahh! Making Sense of Oral Assessments for Mucositis
By
Joan Collela, RN, DNP, APN-BC
;
Claudia Douglas, RN, MA, CNN
;
Joanne Growney, RN, MA, ANP-BC
;
Rebecca Martin, BSN, RN, OCN
;
Phyllis McKiernan, RN, MSN, APN-BC
March 2013, Vol 4, No 3
Background:
Chemotherapy and radiation therapy, the mainstays of current cancer treatment, often result in devastating side effects involving the oral cavity. Mucositis, an inflammatory and/or ulcerative lesion of the oral and/or gastrointestinal tract is a common therapy-related toxicity. Mucositis significantly impacts patients’ overall physical and functional well-being, as well as quality of life. There is strong evidence suggesting that the implementation of preventive strategy, such as patient and family education on the importance of oral hygiene practices, can lower the incidence of mucositis.
Read Article
Impact of Granulocyte Colony-Stimulating Factor and Treatment Modification on Eribulin Mesylate Therapy in Metastatic Breast Cancer Patients with Neutropenia
By
Faria C
;
Craver C
;
Yardley D
;
Cox D
;
Belk K
March 2013, Vol 4, No 3
Background:
Eribulin mesylate (EM) is a microtubule inhibitor shown to improve survival in patients with metastatic breast cancer (MBC) who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease.
Read Article
Impact of Treatment Modification on Treatment Duration in Metastatic Breast Cancer Patients Treated with Eribulin Mesylate
March 2013, Vol 4, No 3
EM is a microtubule inhibitor shown to improve overall survival in metastatic breast cancer patients who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. There are side effects of EM, including neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation.
Read Article
An Assessment of Racial Differences in Toxicities and Supportive Care in Patients with Metastatic Breast Cancer (MBC)
By
Nancy Beegle
;
Sibel Blau, MD
;
Claudio Faria
;
Traci Kalberer
;
Zhixiao Wang
March 2013, Vol 4, No 3
Background:
Racial disparities in clinical outcomes between Caucasian and African American (AA) MBC patients have been identified. Some of these disparities may be attributed to differences in toxicities and access to supportive care interventions.
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma